HOUSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today provides a clinical development and operational update for 2024. "The new year is off to a strong start as we build off positive data generated in 2023 that compel us to advance these studies as quickly as possible and to file for regulatory designations ...

As filed with the Securities and Exchange Commission on March 13, 2024 Registration No. 333-277802 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 To FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIO-PATH HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 2834 (Primary Standard Industrial Classification Code Number) 87-0652870 (I.R.S. Employer Identification N ...

As filed with the Securities and Exchange Commission on March 8, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 TABLE OF CONTENTS FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIO-PATH HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 2834 (Primary Standard Industrial Classification Code Number) 4710 Bellaire Boulevard, Suite 210 Bellaire, Texas 7 ...

Bio-Path Holdings Inc. (NASDAQ:BPTH) Q4 2023 Results Conference Call March 8, 2024 8:30 AM ET Company Participants Will O’Connor - Stern Investor Relations Peter Nielsen - CEO and CFO Anthony Price - SVP, Finance, Accounting and Administration Conference Call Participants Jonathan Aschoff - Roth MKM Operator Good morning, ladies and gentlemen, and welcome to the Bio-Path Holdings Full Year 2023 Earnings Conference Call. [Operator Instructions] Please also note today’s event is being recorded. At this time, ...

HOUSTON, March 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the year ended December 31, 2023 and provided an update on recent corporate developments. "2023 was a year of focused execution, as evidenced by the continued progress across our pipeline of DNAbilize programs," said P ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Common Stock, par value $0.001 per share BPTH The Nasdaq Capital Market Date of report (Date of earliest event reported): March 8, 2024 4710 Bellaire Boulevard, Suite 210, Bellaire, Texas 77401 (Address of principal executive offices) (Zip Code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Indicate by check mark w ...

We have expanded our intellectual property portfolio by filing patent applications that are applicable to our technology and business strategy. Our patent portfolio currently includes five issued patents in the U.S. and 17 issued patents in foreign jurisdictions: | --- | --- | --- | |--------------------------|------------------------------------------------------------|-----------------------| | Patent No. | Title | Date Issued | | US 9,744,187 | P-ethoxy nucleic acids for liposomal formulation | August 29 ...

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on January 23, 2024 Registration No. 333-276239 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 To FORM S-1 (Primary Standard Industrial Classification Code Number) 4710 Bellaire Boulevard, Suite 210 Bellaire, Texas 77401 (832) 742-1357 (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) REGISTRATION STATEMENT UNDER THE SECURITIES AC ...

As filed with the Securities and Exchange Commission on December 22, 2023 TABLE OF CONTENTS BIO-PATH HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 2834 (Primary Standard Industrial Classification Code Number) 4710 Bellaire Boulevard, Suite 210 Bellaire, Texas 77401 (832) 742-1357 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE ...

Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q3 2023 Earnings Call Transcript November 15, 2023 8:30 AM ET Company Participants Will O'Connor - IR, Stern IR Peter Nielsen - President and CEO Anthony Price - SVP of Finance, Accounting and Administration Conference Call Participants Jonathan Aschoff - ROTH MKM Operator Good morning, ladies and gentlemen. Welcome to the Bio-Path Holdings Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] Foll ...